“Our data shows that as many as 20% of breast cancer survivors on aromatase inhibitors will stop taking their medication ...

Dr Jilly O'Hagan says she is "hugely concerned" after three patients in her surgery received a late cancer diagnosis.

The Post Surgery Everyday Bra, manufactured for brands by MAS Femography, combines medical insight and apparel innovation, ...

The drugmaker said the results for giredestrant open the door to adding a treatment option at an early stage of the cancer, ...

By embedding standardized questionnaires and algorithms into routine visits, providers can evaluate risk factors such as age, ...

Roche's ROG.S experimental oral drug giredestrant has been shown to cut the risk of recurrence of a common form of breast ...

The rationale is really strong since we're often making decisions for our patients based on single features or ...

The second-line endocrine therapy landscape in hormone receptor (HR)-positive, HER2-negative advanced breast cancer is ...

The massive study, which was conducted in Sweden and tracked more than 2 million teenage girls and women under age 50 for ...

The study sought to answer questions about how breast cancer risk differs by type of hormonal contraceptive. Doctors say the ...

A real-world analysis of more than 60,000 patients in the US finds median survival increased by almost 7 months from 2011 to ...

Breast Cancer Canada has released its 2025 Annual Progress Report, offering a comprehensive overview of breast cancer care in Canada. The report highlights advances in treatment, screening, and policy ...